Omparo omacetaxine mepesuccinate: Interim Phase II data

ChemGenex reported additional interim data from 81 evaluable CML patients who have failed Gleevec imatinib therapy and have the BCR-ABL T315I mutation in the ongoing, open-label Phase II Study 202 trial. In 49 chronic phase patients, 86% had complete hematologic responses with a median response duration of 9 months, and 41% had a cytogenetic response with a major cytogenetic response rate of 27%. In 17 accelerated phase patients, 35% had overall hematologic responses with a median duration of 7 months. In 15 blast phase patients, 47% had overall hematologic responses with a median duration of 2 months. Data were presented at the American Society of Hematology meeting in New Orleans. ...